{"id":34770,"date":"2021-11-26T09:01:49","date_gmt":"2021-11-26T14:01:49","guid":{"rendered":"http:\/\/parkinson-export.local\/?post_type=clinical-trial&#038;p=34770"},"modified":"2021-11-26T09:31:03","modified_gmt":"2021-11-26T14:31:03","slug":"a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova","status":"publish","type":"clinical-trial","link":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/","title":{"rendered":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson&rsquo;s Disease (PADOVA)"},"content":{"rendered":"<p>This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson&rsquo;s Disease (PD) who are on stable symptomatic PD medication.<\/p>\n<p>You may be eligible if the following apply:<br \/>\n\u2022\tDiagnosis of PD plus one of the other cardinal signs of PD (resting tremor, rigidity), without any other known or suspected cause of parkinsonism<br \/>\n\u2022\tOn symptomatic PD medication for at least 6 months<br \/>\n\u2022\tA diagnosis of PD for at least 6 months to maximum 3 years at screening<\/p>\n","protected":false},"featured_media":34772,"template":"","class_list":["post-34770","clinical-trial","type-clinical-trial","status-publish","has-post-thumbnail","hentry"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.2.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson&#039;s Disease (PD) who are on stable symptomatic PD medication. You may be eligible if the following apply: \u2022 Diagnosis of PD plus one of the other cardinal signs of\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"google-site-verification\" content=\"2AhivUiST2eKQcfei6JBM5Zbf8YQRvHy0kRBp9sDLWo\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.2.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Parkinson Canada -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson\u2019s Disease (PADOVA) - Parkinson Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson&#039;s Disease (PD) who are on stable symptomatic PD medication. You may be eligible if the following apply: \u2022 Diagnosis of PD plus one of the other cardinal signs of\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2021-11-26T14:01:49+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2021-11-26T14:31:03+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:title\" content=\"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson\u2019s Disease (PADOVA) - Parkinson Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson&#039;s Disease (PD) who are on stable symptomatic PD medication. You may be eligible if the following apply: \u2022 Diagnosis of PD plus one of the other cardinal signs of\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/#listItem\",\"name\":\"Clinical Trials\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/#listItem\",\"position\":2,\"name\":\"Clinical Trials\",\"item\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#listItem\",\"name\":\"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson&rsquo;s Disease (PADOVA)\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#listItem\",\"position\":3,\"name\":\"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson&rsquo;s Disease (PADOVA)\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/#listItem\",\"name\":\"Clinical Trials\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\",\"name\":\"Parkinson Canada\",\"description\":\"Parkinson Canada empowers people living with Parkinson\\u2019s and their care partners to thrive. Through advocacy, education, and support, we work to improve access to care, advance research, and build a stronger Parkinson\\u2019s community across Canada. Join us in making a difference.\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"email\":\"info@parkinson.ca\",\"telephone\":\"+18005653000\",\"foundingDate\":\"1965-04-11\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/parkinson.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Parkinson-Canada-logo-23-RGB.jpg\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/parkinsoncanada\",\"https:\\\/\\\/twitter.com\\\/parkinsoncanada\",\"https:\\\/\\\/instagram.com\\\/parkinsoncanada\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm_sAjRqhAaiutx2B9dOqng\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/parkinson-canada\"]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#webpage\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/\",\"name\":\"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson\\u2019s Disease (PADOVA) - Parkinson Canada\",\"description\":\"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication. You may be eligible if the following apply: \\u2022 Diagnosis of PD plus one of the other cardinal signs of\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#breadcrumblist\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/wp-content\\\/uploads\\\/Toronto-Memory-Program-Revised-Logo_FINAL.png\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#mainImage\",\"width\":375,\"height\":180},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/clinical-trial\\\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\\\/#mainImage\"},\"datePublished\":\"2021-11-26T09:01:49+00:00\",\"dateModified\":\"2021-11-26T09:31:03+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"name\":\"Parkinson Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson\u2019s Disease (PADOVA) - Parkinson Canada","description":"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication. You may be eligible if the following apply: \u2022 Diagnosis of PD plus one of the other cardinal signs of","canonical_url":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"2AhivUiST2eKQcfei6JBM5Zbf8YQRvHy0kRBp9sDLWo","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/#listItem","position":1,"name":"Home","item":"https:\/\/www.parkinson.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/#listItem","name":"Clinical Trials"}},{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/#listItem","position":2,"name":"Clinical Trials","item":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#listItem","name":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson&rsquo;s Disease (PADOVA)"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#listItem","position":3,"name":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson&rsquo;s Disease (PADOVA)","previousItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/#listItem","name":"Clinical Trials"}}]},{"@type":"Organization","@id":"https:\/\/www.parkinson.ca\/fr\/#organization","name":"Parkinson Canada","description":"Parkinson Canada empowers people living with Parkinson\u2019s and their care partners to thrive. Through advocacy, education, and support, we work to improve access to care, advance research, and build a stronger Parkinson\u2019s community across Canada. Join us in making a difference.","url":"https:\/\/www.parkinson.ca\/fr\/","email":"info@parkinson.ca","telephone":"+18005653000","foundingDate":"1965-04-11","numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"logo":{"@type":"ImageObject","url":"https:\/\/parkinson.ca\/wp-content\/uploads\/2025\/01\/Parkinson-Canada-logo-23-RGB.jpg","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#organizationLogo"},"image":{"@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#organizationLogo"},"sameAs":["https:\/\/facebook.com\/parkinsoncanada","https:\/\/twitter.com\/parkinsoncanada","https:\/\/instagram.com\/parkinsoncanada","https:\/\/www.youtube.com\/channel\/UCm_sAjRqhAaiutx2B9dOqng","https:\/\/www.linkedin.com\/company\/parkinson-canada"]},{"@type":"WebPage","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#webpage","url":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/","name":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson\u2019s Disease (PADOVA) - Parkinson Canada","description":"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication. You may be eligible if the following apply: \u2022 Diagnosis of PD plus one of the other cardinal signs of","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/www.parkinson.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#breadcrumblist"},"image":{"@type":"ImageObject","url":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/Toronto-Memory-Program-Revised-Logo_FINAL.png","@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#mainImage","width":375,"height":180},"primaryImageOfPage":{"@id":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/#mainImage"},"datePublished":"2021-11-26T09:01:49+00:00","dateModified":"2021-11-26T09:31:03+00:00"},{"@type":"WebSite","@id":"https:\/\/www.parkinson.ca\/fr\/#website","url":"https:\/\/www.parkinson.ca\/fr\/","name":"Parkinson Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/www.parkinson.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Parkinson Canada -","og:type":"article","og:title":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson\u2019s Disease (PADOVA) - Parkinson Canada","og:description":"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication. You may be eligible if the following apply: \u2022 Diagnosis of PD plus one of the other cardinal signs of","og:url":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/","og:image":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png","og:image:secure_url":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png","og:image:width":1000,"og:image:height":600,"article:published_time":"2021-11-26T14:01:49+00:00","article:modified_time":"2021-11-26T14:31:03+00:00","article:publisher":"https:\/\/facebook.com\/parkinsoncanada","twitter:card":"summary_large_image","twitter:site":"@parkinsoncanada","twitter:title":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson\u2019s Disease (PADOVA) - Parkinson Canada","twitter:description":"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication. You may be eligible if the following apply: \u2022 Diagnosis of PD plus one of the other cardinal signs of","twitter:image":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png"},"aioseo_meta_data":{"post_id":"34770","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-01-28 08:48:15","updated":"2025-06-07 08:22:24","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.parkinson.ca\/fr\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/\" title=\"Clinical Trials\">Clinical Trials<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tA Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson\u2019s Disease (PADOVA)\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.parkinson.ca\/fr\/"},{"label":"Clinical Trials","link":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/"},{"label":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson&rsquo;s Disease (PADOVA)","link":"https:\/\/www.parkinson.ca\/fr\/clinical-trial\/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova\/"}],"_links":{"self":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/clinical-trial\/34770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/clinical-trial"}],"about":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/types\/clinical-trial"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/media\/34772"}],"wp:attachment":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/media?parent=34770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}